1343 related articles for article (PubMed ID: 27815355)
1. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
2. A versatile system for rapid multiplex genome-edited CAR T cell generation.
Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
4. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
5. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
6. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
7. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
Choi BD; Yu X; Castano AP; Darr H; Henderson DB; Bouffard AA; Larson RC; Scarfò I; Bailey SR; Gerhard GM; Frigault MJ; Leick MB; Schmidts A; Sagert JG; Curry WT; Carter BS; Maus MV
J Immunother Cancer; 2019 Nov; 7(1):304. PubMed ID: 31727131
[TBL] [Abstract][Full Text] [Related]
9. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
11. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.
Hu W; Zi Z; Jin Y; Li G; Shao K; Cai Q; Ma X; Wei F
Cancer Immunol Immunother; 2019 Mar; 68(3):365-377. PubMed ID: 30523370
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
15. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
17. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
[TBL] [Abstract][Full Text] [Related]
18. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
[TBL] [Abstract][Full Text] [Related]
19. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
20. Paving the way towards universal treatment with allogenic T cells.
Townsend MH; Bennion K; Robison RA; O'Neill KL
Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]